Methods and compositions for treating hypoglycemic disorders

• US 10,188,702 B2
• Filed: 03/08/2017
• Issued: 01/29/2019
• Est. Priority Date: 01/08/2007
• Status: Active Grant

• Current Assignee: Children's Hospital of Philadelphia (Children's Hospital of Philadelphia Foundation)
• Original Assignee: Children's Hospital of Philadelphia (Children's Hospital of Philadelphia Foundation), Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: Stoffers, Doris, De Leon, Diva D., Stanley, Charles
• Primary Examiner(s): Skowronek, Karlheinz R.
• Assistant Examiner(s): Niebauer, Ronald T
• Application Number:
  US15/453,823
• Publication Number:
  US 20180050095A1
• Time in Patent Office: 692 Days
• Field of Search: None
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analog thereof.

Claims

1. A method of treating congenital hyperinsulinism in a subject having congenital hyperinsulinism comprising administering to the subject an effective amount of a peptide wherein the amino acid sequence of the peptide consists of the amino acid sequence set forth in SEQ ID NO:

1.

2. The method of claim 1, wherein the congenital hyperinsulinism is associated with a genetic abnormality or a mutation.

3. The method of claim 2, wherein the genetic abnormality or the mutation is associated with a gene selected from the group consisting of a gene encoding glucokinase (GCK), a gene encoding glutamate dehydrogenase (GLUD-1), and a gene encoding mitochondrial enzyme short-chain 3-hydroxyacyl-CoA dehydrogenase (HADHSC).

4. The method of claim 1, wherein the peptide is administered intravenously, parenterally, orally, intraperitoneally, subcutaneously, or by a combination thereof.

5. The method of claim 4, wherein the peptide is administered subcutaneously.

6. The method of claim 4, wherein the peptide is administered intravenously.

7. The method of claim 1, wherein the peptide is administered by infusion.